natgillin/translations-raw huggingface dataset:
If neutropenia develops (absolute neutrophil count <°1.3°x 103/°µl) it may be appropriate to interrupt or discontinue Mycophenolate mofetil Teva. 
Če se pojavi nevtropenija (absolutno število nevtrofilcev < 1,3 x 103/µl), moramo odmerke zdravila Mofetilmikofenolat Teva zmanjšati ali zdravljenje prekiniti.
Mycophenolate mofetil Teva should not be used during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection (see section 4.6). 
Zdravila Mofetilmikofenolat Teva ne smemo uporabljati med nosečnostjo, razen če ni na voljo primernega alternativnega zdravljenja za preprečitev zavrnitve presadka (glejte poglavje 4.6).
• Abnormalities of the ear (e.g. abnormally formed or absent external ear), external auditory canal atresia (middle ear); 
• nenormalna ušesa (npr. nenormalna oblika ali manjkajoče zunanje/srednje uho), atrezija zunanjega sluhovoda (srednjega ušesa),
Mycophenolate mofetil Teva should not be used in children and adolescents (aged 2 to 18) for heart or liver transplantation. 
Zdravila Mofetilmikofenolat Teva se ne sme uporabljati pri otrocih in mladostnikih (starih od 2 do 18 let) za preprečevanje zavrnitve presajenega srca ali jeter.
In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats at 6 mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90 mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity. 
6 mg/kg/dan pri podganah (vključno z anoftalmijo, agnatijo in hidrocefalijo) ter pri odmerkih 90 mg/kg/dan pri kuncih (vključno s kardiovaskularnimi motnjami in motnjami delovanja ledvic, kot so ektopija srca in ledvic ter preponska in popkovna kila), pri materah pa škodljivih učinkov ni bilo.
Oral Mycophenolate mofetil Teva should be initiated within 72°hours following transplantation. 
Zdravilo Mofetilmikofenolat Teva damo uvodoma peroralno v 72 urah po presaditvi.
Do not crush the tablets. 
Tablet ne smete lomiti ali zmečkati.
• Your womb (uterus) has been removed by surgery (hysterectomy). 
- Če so vam z operacijo odstranili maternico (histerektomija).
Therefore Mycophenolate mofetil Teva is contraindicated in pregnancy unless there are no suitable alternative treatments to prevent transplant rejection. 
Zato je zdravilo Mofetilmikofenolat Teva med nosečnostjo kontraindicirano, razen če za preprečitev zavrnitve presadka ni na voljo primernih alternativnih zdravljenj.
The first dose will be given within 5 days following the transplant operation. 
Odrasli Prvi odmerek boste prejeli v 5 dneh po presaditvenem posegu.
Other medicines and Mycophenolate mofetil Teva 
Druga zdravila in zdravilo Mofetilmikofenolat Teva
Mycophenolate mofetil Teva is contraindicated during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection. 
Zdravilo Mofetilmikofenolat Teva je med nosečnostjo kontraindicirano, razen če za preprečitev zavrnitve presadka ni na voljo primernega alternativnega zdravljenja.
• serious disease of the kidney (BK virus associated nephropathy) 
• resna bolezen ledvic (nefropatija, povezana z virusom BK)
As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90°days after you stop taking Mycophenolate mofetil Teva. 
Kot previdnostni ukrep je za vas ali vašo partnerko priporočljivo, da med zdravljenjem in 90 dni po končanem zdravljenju uporabljate/uporablja zanesljivo obliko kontracepcije.
In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by coadministration with tacrolimus. 
Takrolimus Pri bolnikih z jetrnim presadkom, pri katerih so uvedli mofetilmikofenolat in takrolimus, sprememba AUC in cmax mikofenolne kisline, aktivnega presnovka mofetilmikofenolata, zaradi sočasnega dajanja takrolimusa ni bila pomembna.
Adverse reactions, probably or possibly related to mycophenolate mofetil, reported in patients treated with mycophenolate mofetil in renal, cardiac and hepatic clinical trials when used in combination with ciclosporin and corticosteroids 
Neželeni učinki, verjetno ali možno povezani z mofetilmikofenolatom, ki so se pojavili pri bolnikih, zdravljenih z mofetilmikofenolatom v kombinaciji s ciklosporinom in kortikosteroidi pri kliničnih preskušanjih bolnikov z ledvičnim, srčnim ali jetrnim presadkom.
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. 
Pri dajanju antacidov, kot so magnezijevi in aluminijevi hidroksidi, in zaviralcev protonske črpalke, vključno z lanzoprazolom in pantroprazolom, skupaj z zdravilom Mofetilmikofenolat Teva, so opazili zmanjšano izpostavljenost mikofenolni kislini.
Mycophenolate mofetil Teva 500 mg film-coated tablets are available in PVC/PVdC-aluminium blisters in pack sizes of 50 or 150 or 50 x 1 tablets per carton. 
Zdravilo Mofetilmikofenolat Teva 500 mg filmsko obložene tablete je na voljo v PVC/PVdC aluminijastem pretisnem omotu, v pakiranjih po 50 ali 150 ali 50 x 1 tableta v škatli
Caution should be exercised when switching combination therapy from regimens containing immunosuppressants, which interfere with MPA enterohepatic recirculation, e.g. ciclosporin, to others devoid of this effect, e.g. tacrolimus, sirolimus, belatacept, or vice versa, as this might result in changes of MPA exposure. 
Pri prehodu s kombiniranega zdravljenja s shemo z imunosupresivi, ki ovirajo enterohepatični obtok mikofenolne kisline (npr. ciklosporin) na druge, ki nimajo takega učinka (npr. takrolimus, sirolimus, belatacept), ali obratno, je potrebna previdnost, saj to lahko vodi k spremembam izpostavljenosti mikofenolni kislini.
Mycophenolate mofetil Teva treatment should not be initiated in women of child bearing potential without providing a pregnancy test result to rule out unintended use in pregnancy (see section 4.6). 
Zdravljenja z zdravilom Mofetilmikofenolat Teva ne smemo uvesti pri bolnicah v rodni dobi, ki ne zagotovijo izvida testa nosečnosti, da izključimo nenamerno uporabo zdravila med nosečnostjo (glejte poglavje 4.6).
Precautions to be taken before handling or administering the medicinal product Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Mycophenolate mofetil Teva tablets should not be crushed. 
Previdnostni ukrepi, potrebni pred ravnanjem z zdravilom ali dajanjem zdravila Ker ima mofetilmikofenolat dokazane teratogene učinke pri podganah in kuncih, filmsko obloženih tablet zdravila Mofetilmikofenolat Teva ne smemo drobiti.
There have been published reports of bronchiectasis in adults and children who received mycophenolate mofetil in combination with other immunosuppressants. 
Objavljeni so bili primeri bronhiektaze pri odraslih in otrocih, ki so prejeli mofetilmikofenolat v kombinaciji z drugimi imunosupresivi.
No substantial alteration of MPA pharmacokinetics is anticipated and mycophenolate mofetil dose adjustment is not required. 
Znatnih sprememb v farmakokinetiki mikofenolne kisline ni pričakovati, zato prilagajanje odmerkov zdravila Mofetilmikofenolat Teva ni potrebno.
Gingival hyperplasia (≥1/100 to <1/10), colitis including cytomegalovirus colitis (≥1/100 to <1/10), 
Prebavila Gingivalna hiperplazija (≥ 1/100 do < 1/10), kolitis, vključno s kolitisom, ki ga povzroča citomegalovirus
Congenital malformations have been observed post-marketing in children of patients exposed to mycophenolate mofetil in combination with other immunosuppressants, see section 4.6. 
Po prihodu zdravila na trg so pri otrocih bolnikov, ki so bili izpostavljeni zdravilu Mofetilmikofenolat Teva v kombinaciji z drugimi imunosupresivi, poročali o kongenitalnih malformacijah; glejte poglavje 4.6.
Do not break or crush them. 
Kapsul ne smete lomiti ali zmečkati.
• inflammation of the colon which causes abdominal pain or diarrhoea (sometimes caused by cytomegalovirus), ulcer of the stomach and/or duodenum, inflammation of the stomach, 
• vnetje debelega črevesa, ki povzroča bolečine v trebuhu ali drisko (včasih posledica citomegalovirusa),
Mycophenolate mofetil Teva contains sodium 
Zdravilo Mofetilmikofenolat Teva vsebuje natrij
However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6°years of age, when compared to adults: diarrhoea, sepsis, leucopenia, anaemia and infection. 
zlasti pri otrocih, mlajših od 6 let: driska, sepsa, levkopenija, anemija in okužba.
Capsule content Pregelatinised starch (maize) Povidone K-30 
Kapsula vsebuje predgeliran koruzni škrob povidon K-30 premrežen natrijev karmelozat magnezijev stearat
Hypogammaglobulinaemia has been reported in patients receiving mycophenolate mofetil in combination with other immunosuppressants (frequency not known). 
Bolezni imunskega sistema O hipogamaglobulinemiji so poročali pri bolnikih, ki so mofetilmikofenolat prejemali v kombinaciji z drugimi imunosupresivi (pogostnost ni poznana).
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Mycophenolate mofetil Teva, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). 
Bolniki, ki prejemajo kombinacije imunosupresivnih zdravil, vključno z zdravilom Mofetilmikofenolat Teva , so izpostavljeni povečanem tveganju nastanka limfomov in drugih malignih sprememb, zlasti kožnih (glejte poglavje 4.8).
PRCA may resolve with dose reduction or cessation of Mycophenolate mofetil Teva therapy. 
PRCA je lahko reverzibilna z zmanjšanjem odmerka ali s prekinitvijo zdravljenja z zdravilom Mofetilmikofenolat Teva.
Changes to Mycophenolate mofetil Teva therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimise the risk of graft rejection (see section 4.8). 
Pri bolnikih s presadki se zaradi zmanjšanja tveganja za zavrnitev presadka spremembe v zdravljenju z zdravilom Mofetilmikofenolat Teva lahko uvaja le pod ustreznim nadzorom (glejte poglavje 4.8).
Therefore women with childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting Mycophenolate mofetil Teva therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. 
Zato morajo ženske v rodni dobi pred začetkom zdravljenja, med zdravljenjem in šest tednov po končanem zdravljenju z zdravilom Mofetilmikofenolat Teva uporabljati vsaj eno zanesljivo obliko kontracepcije (glejte poglavje 4.3), razen če niso izbrale metode vzdržnosti.
Mycophenolate mofetil Teva 250 mg hard capsules are available in PVC/PVdC-aluminium blisters in pack sizes of 100 or 300 or 100 x 1 capsules per carton. 
Zdravilo Mofetilmikofenolat Teva 250 mg trde kapsule je na voljo v prozornem PVC/PVdC aluminijastem pretisnem omotu, v pakiranjih po 100 ali 300 ali 100 x 1 kapsula v škatli.
The following undesirable effects cover adverse reactions from post-marketing experience The types of adverse reactions reported during post-marketing with mycophenolate mofetil are similar to those seen in the controlled renal, cardiac and hepatic transplant studies. 
Neželeni učinki, ki so se pojavili v postmarketinških raziskavah zdravljenja z mofetilmikofenolatom, so podobni neželenim učinkom v nadzorovanih raziskavah bolnikov z ledvičnim, srčnim in jetrnim presadkom.
Note: 501 (2°g mycophenolate mofetil daily), 289 (3°g mycophenolate mofetil daily) and 277 (2°g intravenous/3°g oral mycophenolate mofetil daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively. 
(2 g mofetilmikofenolata na dan), 289 (3 g mofetilmikofenolata na dan) in 277 (2 g i.v./3 g peroralne oblike mofetilmikofenolata na dan) bolnikov.
Do not stop taking Mycophenolate mofetil Teva because you feel better. 
Če ste prenehali jemati zdravilo Mofetilmikofenolat Teva Zdravljenja z zdravilom Mofetilmikofenolat Teva ne prekinjajte, ker se počutite bolje.
Mycophenolate mofetil Teva is a medicine that is used to suppress immune activity. 
Zdravilo Mofetilmikofenolat Teva spada v skupino zdravil, znano kot zdravila za zaviranje imunske odzivnosti.
It is recommended that mycophenolate mofetil should not be administered concomitantly with azathioprine because such concomitant administration has not been studied. 
Ne priporočamo sočasnega dajanja zdravila Mofetilmikofenolat Teva in azatioprina, ker kombiniranega jemanja teh zdravil niso proučevali.
• accumulation of fluid in the lung, shortness of breath, cough 
• krvnih žil kopičenje tekočine v pljučih, kratka sapa, kašelj
Mycophenolate mofetil Teva should not be given to women of childbearing potential who are not using highly effective contraception (see section 4.6). 
Zdravila Mofetilmikofenolat Teva ne smemo uporabljati pri bolnicah v rodni dobi, ki ne uporabljajo zelo učinkovitih kontracepcijskih metod (glejte poglavje 4.6).
Contraception in men taking Mycophenolate mofetil Teva 
Kontracepcija pri moških, ki jemljejo zdravilo Mofetilmikofenolat Teva
Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when mycophenolate mofetil was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection). 
30 % in AUC0-12h mikofenolne kisline za 25 %, kliničnih posledic (zavrnitve presadka) pa ni bilo.
CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30-50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section 4.4). 
Ciklosporin A vpliva na enterohepatični obtok mikofenolne kisline in s tem zmanjša izpostavljenost mikofenolni kislini za 30 - 50 % pri bolnikih z ledvičnim presadkom, ki so bili zdravljeni z mofetilmikofenolata in ciklosporinom A, v primerjavi z bolniki, ki so prejemali sirolimus ali belatacept in podobne odmerke mofetilmikofenolata (glejte tudi poglavje 4.4).
Oral Mycophenolate mofetil Teva should be initiated within 5 days following transplantation. 
V začetku damo zdravilo Mofetilmikofenolat Teva peroralno v 5 dneh po presaditvi.
Mycophenolate mofetil Teva should not be given to women who are breastfeeding (see section 4.6). 
Zdravila Mofetilmikofenolat Teva ne smemo uporabljati pri bolnicah, ki dojijo (glejte poglavje 4.6).
If you answer yes to any of the following questions talk to your doctor before you start to take Mycophenolate mofetil Teva: 
Če na katero od spodaj naštetih vprašanj odgovorite pritrdilno, se pred jemanjem zdravila Mofetilmikofenolat
Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil (see section 4.4). 
Bolezni krvi in limfatičnega sistema Pri zdravljenju z mofetilmikofenolatom so poročali o primerih čiste aplazije rdečih krvnih celic (PRCA) (glejte poglavje 4.4).
• The need to avoid foetal exposure: Contraceptive requirements for patients of reproductive potential prior to, during and after treatment with mycophenolate mofetil. 
• Nujnost izogibanja izpostavljenosti ploda Opisane bodo zahteve za kontracepcijo za bolnike in bolnice v rodni dobi pred, med in po zdravljenju z mofetilmikofenolatom, zahteve za kontracepcijo za spolno aktivne bolnike (vključno z vazektomiziranimi) in bolnice v rodni dobi ter potrebo po kontracepciji pred, med in po zdravljenju z mofetilmikofenolatom,
When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. 
Pri primerjavi deležev zavrnitve presadka ali deležev izgube presadka med bolniki, ki so jemali zdravilo Mofetilmikofenolat Teva in zaviralce protonske črpalke ter bolniki, ki so jemali zdravilo Mofetilmikofenolat Teva in niso jemali zaviralcev protonske črpalke, niso opazili značilnih razlik.
Mycophenolate mofetil Teva 250 mg Capsules 
Mofetilmikofenolat Teva 250 mg kapsule
values similar to those seen in adult renal transplant patients receiving mycophenolate mofetil at a dose of 1°g BID in the early and late post-transplant period. 
18 let), ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan. Ti odmerki so dali podobne vrednosti AUC mikofenolne kisline kot pri odraslih bolnikih z ledvičnim presadkom, ki so prejemali mofetilmikofenolat v odmerku 1 g dvakrat na dan v začetnem in poznejšem obdobju po presaditvi.
It is recommended that patients who develop persistent pulmonary symptoms, such as cough and dyspnoea, are investigated. 
pri katerih pulmonalni simptomi, kot sta kašelj in dispneja, vztrajajo, je priporočljivo pregledati.
Organic anion transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA's disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides' biliary excretion. 
Na razporeditev mikofenolne kisline vplivajo organski anionski prenašalni polipeptidi (OATP - Organic anion-transporting polypeptides) in protein za multiplo odpornost na zdravila 2 (MRP2 - Multidrug resistance-associated protein 2).
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leucoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Mycophenolate mofetil Teva. 
Pri bolnikih, zdravljenih z imunosupresivi, vključno z zdravilom Mofetilmikofenolat Teva, so poročali o primerih nefropatije, povezane z virusom BK, kot tudi progresivne multifokalne levkoencefalopatije (PML), povezane z virusom JC.
Mycophenolate mofetil Teva, the contraceptive requirements for both male and female patients and what to do in case of pregnancy during treatment with Mycophenolate mofetil Teva. 
zahteve po kontracepciji za bolnike in bolnice ter da bi vedeli, kaj storiti v primeru zanositve med zdravljenjem z zdravilom Mofetilmikofenolat Teva.
Do not take Mycophenolate mofetil Teva, 
Ne jemljite zdravila Mofetilmikofenolat Teva:
A study of the co-administration of mycophenolate mofetil (1°g BID) and combined oral contraceptives containing ethinylestradiol (0.02°mg to 0.04°mg) and levonorgestrel (0.05°mg to 0.15°mg), desogestrel (0.15°mg) or gestodene (0.05°mg to 0.10°mg) conducted in 18 non-transplant women (not taking other immunosuppressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of mycophenolate mofetil on the ovulation suppressing action of the oral contraceptives. 
Bolnice, ki jemljejo peroralne kontraceptive V študiji je 18 žensk brez presadka (drugih imunosupresivov niso jemale) sočasno prejemalo 1 g mofetilmikofenolata dvakrat na dan in kombinirane kontraceptive, ki so vsebovali etinilestradiol (0,02 mg do 0,04 mg) in levonorgestrel (0,05 mg do 0,15 mg), desogestrel (0,15 mg) ali gestoden (0,05 mg do 0,10 mg).
PC: 
Pokrovček:
Elderly patients receiving Mycophenolate mofetil Teva as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals. 
Pri starejših bolnikih, ki prejemajo zdravilo Mofetilmikofenolat Teva kot del kombinacije imunosupresivnega režima, je v primerjavi z mlajšimi tveganje za pojav določenih okužb (vključno s citomegalovirusno tkivno invazivno boleznijo), krvavitev v prebavilih in pljučnega edema lahko večje.
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA • Načrt za obvladovanje tveganj (RMP)
AcMPAG is pharmacologically active and is suspected to be responsible for some of MMF´s side effects (diarrhoea, leucopenia). 
Ta je farmakološko aktiven in verjetno odgovoren za nekaj neželenih učinkov mofetilmikofenolata
How to take Mycophenolate mofetil Teva 
Kako jemati zdravilo Mofetilmikofenolat Teva
Spontaneous abortion (rate of 45% to 49%) and congenital malformations (estimated rate of 23% to 27%) have been reported following MMF exposure during pregnancy. 
Po izpostavljenosti mofetilmikofenolatu med nosečnostjo so poročali o spontanem splavu (ocenjeni delež 45 % do 49 %) in kongenitalnih malformacijah (ocenjeni delež
Intravenous mycophenolate mofetil should be administered for the first 4°days following hepatic transplant, with oral Mycophenolate mofetil Teva initiated as soon after this as it can be tolerated. 
Odrasli Prve 4 dni po presaditvi jeter je treba dajati mofetilmikofenolat intravensko, takoj ko je bolnik sposoben požirati,
In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g taken twice a day [BID], morning and evening) were administered to hepatic transplant patients taking tacrolimus. 
Nasprotno, po dajanju večkratnih odmerkov mofetilmikofenolata (1,5 g dvakrat na dan, zjutraj in zvečer) bolnikom z jetrnim presadkom, ki so jemali takrolimus, se je AUC takrolimusa povečala za približno
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia and hydrocephaly) in the first generation offspring in the absence of maternal toxicity. 
V študijah fertilnosti in reproduktivnosti so peroralni odmerki po 4,5 mg/kg/dan pri podganjih samicah povzročili malformacije
Do not take Mycophenolate mofetil Teva if you are breast-feeding. 
Dojenje Ne jemljite zdravila Mofetilmikofenolat Teva, če dojite.
Mycophenolate mofetil Teva film-coated tablets should be handled with care. 
Zdravilo Mofetilmikofenolat Teva tablete je treba uporabljati previdno Tablet ne drobite.
• Are you taking any medicines containing: o azathioprine or other immunosuppressive agents (which are sometimes given to patients after a transplant operation), o cholestyramine (used to treat patients with high blood cholesterol), o rifampicin (antibiotic), o antacids or proton pump inhibitors (used for acid problem in your stomach such as indigestion), o phosphate binders (used in patients with chronic kidney failure to reduce the absorption of phosphate), o antibiotics (used to treat bacterial infections), o isavuconazole (used to treat fungal infections), o telmisartan (used to treat high blood pressure) o or any other medicines (including those you can buy without a prescription) that your doctor does not know about? 
o antacide ali zaviralce protonske črpalke (uporabljajo se pri težavah s kislino v želodcu, kot je dispepsija), o fosfatne vezalce (uporabljajo jih za zmanjšanje absorpcije fosfatov pri bolnikih s kronično ledvično odpovedjo), o antibiotike (uporabljajo se za zdravljenje bakterijskih okužb),
Therefore you should limit your exposure to sunlight and ultraviolet (UV) light by wearing appropriate protective clothing and using a sunscreen with a high protection factor. 
Ker zdravilo Mofetilmikofenolat Teva zmanjša obrambno sposobnost vašega organizma, obstaja zvečana možnost nastanka kožnega raka, zato se je treba izogibati sončni svetlobi in ultravijoličnim (UV) žarkom z uporabo zaščitnih oblačil in sončne kreme z visokim zaščitnim faktorjem.
The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18°years who were given 600°mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1°g mycophenolate mofetil twice daily. 
18 let, ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan, sta bila podobna neželenim učinkom, opaženim pri odraslih bolnikih, ki so prejemali 1 g mofetilmikofenolata dvakrat na dan. Naslednji neželeni učinki povezani z zdravljenjem pa so bili v primerjavi z odraslimi pogostejši pri pediatrični populaciji,